<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736187</url>
  </required_header>
  <id_info>
    <org_study_id>Antibiotics for SSI</org_study_id>
    <nct_id>NCT03736187</nct_id>
  </id_info>
  <brief_title>Antibiotics for Prevention of SSI in Obese Women Undergoing CS</brief_title>
  <official_title>Combination Vs Single Antibiotics for Prevention of SSI in Obese Women Undergoing CS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of cephalexin plus metronidazole on SSI better than cephalexin alone in obese women
      undergoing CS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison between efficacy of cephalexin alone and cephalexin plus metronidazole on surgical
      site infection in obese women undergoing CS and follow up of any signs of wound infection
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 Groups of obese women under elective cesarean section</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Two equal groups,140 women in each group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Wound infection</measure>
    <time_frame>One week</time_frame>
    <description>Fever, redness, ecchymosis and tenderness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Cephalexin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group a will receive cephalexin 1gm before skin incision intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalexin &amp;metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>Giving cephalexin and metronidazole in one group &amp;cephalexin alone in another group</description>
    <arm_group_label>Cephalexin</arm_group_label>
    <arm_group_label>Cephalexin &amp;metronidazole</arm_group_label>
    <other_name>Metronidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obese women under elective CS

        Exclusion Criteria:

          -  immunodeficient women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Abeer mohammed abd allah elsayed</investigator_full_name>
    <investigator_title>Cairo governorate,hadaik elqoba,elkhalig elmasry street</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

